ArticleHeart rhythm2026
Amiodarone's impact on substrate mapping for scar-related ventricular tachycardia: Insights from personalized heart digital twins.
Article in Heart rhythm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSubstrate mapping and ablation for scar-related ventricular tachycardia (VT) are often performed with concomitant amiodarone (AMD), which can modify VT inducibility and alter electrogram (EGM) signatures of arrhythmogenic substrate.
objectiveThis study aimed to evaluate how AMD influences VT inducibility and bipolar EGM markers using heart digital twins.
methodsThe effects of AMD at 2 therapeutic concentrations were characterized using heart digital twins incorporating patient-specific ischemic substrate distributions. VT inducibility was tested from multiple sites, and the reentrant circuits were characterized. Identified features of virtual electroanatomic maps included low-voltage, prolonged-duration, high-fractionation EGMs and isochronal crowding (IC) zones. Composite multiple-wavefront pacing maps were used to reduce electroanatomic map dependence on wavefront direction.
resultsAMD did not significantly change overall VT inducibility, although a nonsignificant trend toward fewer inducible sites emerged at higher doses. At the VT circuit level, several baseline circuits disappeared, new drug-associated pathways emerged, and persistent morphologies tended to exhibit longer cycle lengths. AMD broadened regions classified as abnormal by voltage, duration, and fractionation, expanding the apparent substrate and reducing mapping specificity. With a single pacing site, IC zones were within 9 mm of the critical isthmus, more targeted than abnormal signal features, and not appreciably expanded by AMD. Combining multiple pacing orientations markedly improved colocalization without loss of specificity.
conclusionConcomitant AMD alters VT morphology and expands abnormal regions identified during substrate mapping, potentially obscuring critical ablation targets. Functional mapping strategies emphasizing IC and incorporating multiple-wavefront directions may improve long-term procedural success of scar-related VT ablation, particularly when AMD cannot be withdrawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.